

**Table S1. Patient-characteristics of the melanoma cohort, Related to Figure 4**

Overall (n=88)	
Male (%)	54 (61.4)
Age <sup>a</sup> (years, median, IQR)	62.5 (53.8, 69.5)
M-stage <sup>a,b</sup> (%)	
M1a	16 (18.2)
M1b	8 (9.1)
M1c	44 (50.0)
M1d	20 (22.7)
BRAF V600E/K positive (%)	31 (35.2)
Lactate dehydrogenase <sup>a</sup> (median, IQR)	189.0 (156.0, 238.0)
Treatment before biopsy (%)	
Ipilimumab	43 (48.9)
Targeted therapy	14 (15.9)
TIL-therapy	1 (1.1)
Treatment (%)	
Anti-PD1 monotherapy	82 (93.2)
Anti-PD1 + anti-CTLA4	6 (6.7)

<sup>a</sup>At start treatment; <sup>b</sup> M-stage according to the 8th edition American Joint Committee on Cancer (AJCC8) cancer staging system. IQR, interquartile range.